Literature DB >> 24639038

Cost effectiveness of a pharmacist-led information technology intervention for reducing rates of clinically important errors in medicines management in general practices (PINCER).

Rachel A Elliott1, Koen D Putman, Matthew Franklin, Lieven Annemans, Nick Verhaeghe, Martin Eden, Jasdeep Hayre, Sarah Rodgers, Aziz Sheikh, Anthony J Avery.   

Abstract

BACKGROUND AND
OBJECTIVE: We recently showed that a pharmacist-led information technology-based intervention (PINCER) was significantly more effective in reducing medication errors in general practices than providing simple feedback on errors, with cost per error avoided at £79 (US$131). We aimed to estimate cost effectiveness of the PINCER intervention by combining effectiveness in error reduction and intervention costs with the effect of the individual errors on patient outcomes and healthcare costs, to estimate the effect on costs and QALYs.
METHODS: We developed Markov models for each of six medication errors targeted by PINCER. Clinical event probability, treatment pathway, resource use and costs were extracted from literature and costing tariffs. A composite probabilistic model combined patient-level error models with practice-level error rates and intervention costs from the trial. Cost per extra QALY and cost-effectiveness acceptability curves were generated from the perspective of NHS England, with a 5-year time horizon.
RESULTS: The PINCER intervention generated £2,679 less cost and 0.81 more QALYs per practice [incremental cost-effectiveness ratio (ICER): -£3,037 per QALY] in the deterministic analysis. In the probabilistic analysis, PINCER generated 0.001 extra QALYs per practice compared with simple feedback, at £4.20 less per practice. Despite this extremely small set of differences in costs and outcomes, PINCER dominated simple feedback with a mean ICER of -£3,936 (standard error £2,970). At a ceiling 'willingness-to-pay' of £20,000/QALY, PINCER reaches 59 % probability of being cost effective.
CONCLUSIONS: PINCER produced marginal health gain at slightly reduced overall cost. Results are uncertain due to the poor quality of data to inform the effect of avoiding errors.

Entities:  

Mesh:

Year:  2014        PMID: 24639038     DOI: 10.1007/s40273-014-0148-8

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  70 in total

1.  Valuing the economic benefits of complex interventions: when maximising health is not sufficient.

Authors:  Katherine Payne; Marion McAllister; Linda M Davies
Journal:  Health Econ       Date:  2012-02-06       Impact factor: 3.046

2.  Ten-year trends in hospital admissions for adverse drug reactions in England 1999-2009.

Authors:  Tai-Yin Wu; Min-Hua Jen; Alex Bottle; Mariam Molokhia; Paul Aylin; Derek Bell; Azeem Majeed
Journal:  J R Soc Med       Date:  2010-06       Impact factor: 5.344

3.  A guide to cost-effectiveness acceptability curves.

Authors:  Elisabeth Fenwick; Sarah Byford
Journal:  Br J Psychiatry       Date:  2005-08       Impact factor: 9.319

Review 4.  Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.

Authors:  Brennan M R Spiegel; Chiun-Fang Chiou; Joshua J Ofman
Journal:  Arthritis Rheum       Date:  2005-04-15

5.  Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment.

Authors:  U F Haustein; M Rytter
Journal:  J Eur Acad Dermatol Venereol       Date:  2000-09       Impact factor: 6.166

6.  Patient-based utilities for bipolar disorder-related health states.

Authors:  Dennis A Revicki; Jennifer Hanlon; Silas Martin; Laszlo Gyulai; S Nassir Ghaemi; Frances Lynch; Sally Mannix; Leah Kleinman
Journal:  J Affect Disord       Date:  2005-08       Impact factor: 4.839

7.  Amiodarone-associated thyroid dysfunction: risk factors in adults with congenital heart disease.

Authors:  S A Thorne; I Barnes; P Cullinan; J Somerville
Journal:  Circulation       Date:  1999-07-13       Impact factor: 29.690

Review 8.  Health-state utilities in liver disease: a systematic review.

Authors:  David J McLernon; John Dillon; Peter T Donnan
Journal:  Med Decis Making       Date:  2008-04-18       Impact factor: 2.583

Review 9.  A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder.

Authors:  K Soares-Weiser; Y Bravo Vergel; S Beynon; G Dunn; M Barbieri; S Duffy; J Geddes; S Gilbody; S Palmer; N Woolacott
Journal:  Health Technol Assess       Date:  2007-10       Impact factor: 4.014

10.  Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.

Authors:  D Revicki; M K Willian; J-H Saurat; K A Papp; J-P Ortonne; C Sexton; A Camez
Journal:  Br J Dermatol       Date:  2007-11-28       Impact factor: 9.302

View more
  11 in total

1.  Research into practice: safe prescribing.

Authors:  Anthony J Avery; Sarah Rodgers; Bryony Dean Franklin; Rachel A Elliott; Rachel Howard; Sarah P Slight; Glen Swanwick; Richard Knox; Gill Gookey; Nick Barber; Aziz Sheikh
Journal:  Br J Gen Pract       Date:  2014-05       Impact factor: 5.386

Review 2.  Professional, structural and organisational interventions in primary care for reducing medication errors.

Authors:  Hanan Khalil; Brian Bell; Helen Chambers; Aziz Sheikh; Anthony J Avery
Journal:  Cochrane Database Syst Rev       Date:  2017-10-04

3.  'The big buzz': a qualitative study of how safe care is perceived, understood and improved in general practice.

Authors:  Carl de Wet; Paul Bowie; Catherine O'Donnell
Journal:  BMC Fam Pract       Date:  2018-06-09       Impact factor: 2.497

4.  Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice.

Authors:  Rachel A Elliott; Lukasz Tanajewski; Georgios Gkountouras; Anthony J Avery; Nick Barber; Rajnikant Mehta; Matthew J Boyd; Asam Latif; Antony Chuter; Justin Waring
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

5.  Improving Transplant Medication Safety Through a Technology and Pharmacist Intervention (ISTEP): Protocol for a Cluster Randomized Controlled Trial.

Authors:  Casey L Hall; Cory E Fominaya; Mulugeta Gebregziabher; Sherry K Milfred-LaForest; Kelsey M Rife; David J Taber
Journal:  JMIR Res Protoc       Date:  2019-10-01

6.  Exploration of prescribing error reporting across primary care: a qualitative study.

Authors:  Nicola Hall; Kathryn Bullen; John Sherwood; Nicola Wake; Scott Wilkes; Gemma Donovan
Journal:  BMJ Open       Date:  2022-01-25       Impact factor: 2.692

7.  Understanding factors influencing uptake and sustainable use of the PINCER intervention at scale: A qualitative evaluation using Normalisation Process Theory.

Authors:  Libby Laing; Nde-Eshimuni Salema; Mark Jeffries; Azwa Shamsuddin; Aziz Sheikh; Antony Chuter; Justin Waring; Anthony Avery; Richard N Keers
Journal:  PLoS One       Date:  2022-09-19       Impact factor: 3.752

Review 8.  The economics of medicines optimization: policy developments, remaining challenges and research priorities.

Authors:  Rita Faria; Marco Barbieri; Kate Light; Rachel A Elliott; Mark Sculpher
Journal:  Br Med Bull       Date:  2014-09       Impact factor: 4.291

9.  The Rise of Patient Safety-II: Should We Give Up Hope on Safety-I and Extracting Value From Patient Safety Incidents? Comment on "False Dawns and New Horizons in Patient Safety Research and Practice".

Authors:  Andrew Carson-Stevens; Liam Donaldson; Aziz Sheikh
Journal:  Int J Health Policy Manag       Date:  2018-07-01

10.  Economic impact of potentially inappropriate prescribing and related adverse events in older people: a cost-utility analysis using Markov models.

Authors:  Frank Moriarty; Caitriona Cahir; Kathleen Bennett; Tom Fahey
Journal:  BMJ Open       Date:  2019-01-30       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.